Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000505 |
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia |
Drug: tissue plasminogen activator Procedure: angioplasty, transluminal, percutaneous coronary |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Study Start Date: | April 1983 |
Estimated Study Completion Date: | December 1990 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women under age 76. Patients had acute myocardial infarction.
Investigator: | Joseph Babb | Bridgeport Hospital |
Investigator: | Jeffery Borer | Weill Medical College of Cornell University |
Investigator: | Bernard Chaitman | St. Louis University Medical Center |
Investigator: | James Chesebro | Mayo Foundation |
Investigator: | Richard Davison | Northwestern University |
Investigator: | Harold Dodge | University of Washington |
Investigator: | Frederick Feit | New York University Medical Center |
Investigator: | Charles Francis | Yale University |
Investigator: | Joel Gore | University of Massachusetts |
Investigator: | Michael Herman | New York Medical College |
Investigator: | Morrison Hodges | University of Minnesota |
Investigator: | Harvey Kemp | St. Luke's-Roosevelt Institute for Health Sciences |
Investigator: | Genell Knatterud | Maryland Medical Research Institute |
Investigator: | Costas Lambrew | Maine Medical Center |
Investigator: | Philip Ludbrook | Washington University School of Medicine |
Investigator: | Kenneth Mann | University of Vermont |
Investigator: | John Markis | Beth Israel Hospital |
Investigator: | John Morrison | North Shore University Hospital |
Investigator: | Hiltrud Mueller | Montefiore Medical Center |
Investigator: | Eric Powers | Columbia University |
Investigator: | Robert Roberts | Baylor College of Medicine |
Investigator: | Williams Rogers | University of Alabama at Birmingham |
Investigator: | Allan Ross | George Washington University |
Investigator: | Thomas Ryan | University Hospital Inc. |
Investigator: | Marc Schweiger | Baystate Medical Center |
Investigator: | Gerald Timmis | William Beaumont Hospitals |
Investigator: | James Willerson | University of Texas |
Investigator: | David Williams | Rhode Island Hospital |
Investigator: | Barry Zaret | Yale University |
Study ID Numbers: | 24 |
Study First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000505 |
Health Authority: | United States: Federal Government |
Arterial Occlusive Diseases Heart Diseases Myocardial Ischemia Vascular Diseases Tissue Plasminogen Activator Ischemia Arteriosclerosis |
Coronary Disease Necrosis Infarction Myocardial Infarction Plasminogen Coronary Artery Disease |
Fibrin Modulating Agents Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents |
Fibrinolytic Agents Cardiovascular Diseases Cardiovascular Agents Pharmacologic Actions |